Aspenbio Pharma (APPY) 1.71 $APPY
Venaxis Files Response to FDA's Request for Additional Information
PR Newswire - Wed Dec 03, 3:35PM CST
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood-based test designed to aid emergency room clinicians in identifying children, adolescent, and young adult patients who are at low risk for appendicitis, today announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission. Venaxis will provide a business update, including discussion on the APPY1 FDA submission, on Monday, December 8, 2014, at 4:30 p.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 1.71 (-0.01)
Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:32AM CST
Venaxis, Inc. (APPY) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
ICUI: 80.95 (-1.04), GWPH: 72.41 (+1.18), APPY: 1.71 (-0.01), OSUR: 9.49 (-0.25)
Venaxis to Present at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum
PR Newswire - Thu Nov 13, 3:15PM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will be presenting at the Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum being held in New York on November 20, 2014.
APPY: 1.71 (-0.01)
Venaxis: Latest Clinical Data Reveals Huge Market Potential
Blair O'Neill - Seeking Alpha - Wed Oct 29, 10:48AM CDT
Introduction The APPY1 test is a 20 minute diagnostic tool that can be used to rule out the presence of acute appendicitis for the expected price of $80. Venaxis' ( APPY ) goal for the APPY1 test is to reduce the number of CT scans, the use of...
APPY: 1.71 (-0.01)
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ACEP14
PR Newswire - Mon Oct 27, 3:30PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low probability for appendicitis, today announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14). The clinical trial involved 29 U.S. hospital sites recruiting patients aged 2 - 20 from January 2013 through January 2014. Results were presented by Lead Principal Investigator Dr. David S. Huckins, M.D.
APPY: 1.71 (-0.01)
Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14
PR Newswire - Tue Oct 14, 3:05PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low probability for appendicitis, today announced that results of the company's pivotal APPY1 clinical trial will be presented by Dr. David S. Huckins, M.D., Lead Principal Investigator, at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
APPY: 1.71 (-0.01)
Venaxis to Present at September Investor Conferences
PR Newswire - Thu Aug 28, 8:15AM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will present at three upcoming investor conferences: the Rodman & Renshaw 16th Annual Global Investment Conference being held in New York on September 8-10, 2014, the Aegis Capital 2014 Healthcare & Technology Conference being held in Las Vegas on September 10-13, 2014, and the 5th Annual Craig-Hallum Alpha Select Conference being held in New York on September 18, 2014.
APPY: 1.71 (-0.01)
Venaxis to Provide Business Update, including FDA Submission Update
PR Newswire - Thu Aug 07, 3:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will provide a business update, including discussion on the progress of the APPY1 FDA submission, on Monday, August 11, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 1.71 (-0.01)
Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference
PR Newswire - Tue Aug 05, 3:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity 34th Annual Growth Conference, to be held August 13-14, 2014, at the Intercontinental Boston in Boston, MA.
APPY: 1.71 (-0.01)
AspenBio Pharma Down 15.9%, Shares Slide into the Red (APPY)
Comtex SmarTrend(R) - Wed Jul 16, 10:07AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 15.9% to $1.88 on 6.3x average daily volume. AspenBio Pharma has traded 1.3 million shares thus far today, vs. average volume of 206,000 shares per day. The stock has underperformed the Dow (-15.9% to the Dow's 0.2%) and underperformed the S&P 500 (-15.9% to the S&P's 0.2%) during today's trading.
APPY: 1.71 (-0.01)
Venaxis Reports on Recent FDA Submission Activities
PR Newswire - Wed Jul 16, 8:15AM CDT
CASTLE ROCK, Colo., July 16, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, updated on recent activities concerning its U. S. Food and Drug Administration (FDA) submission for the APPY1 Test that was filed in March 2014. The FDA has reviewed the submission, and provided Venaxis with questions and information requests on the submission.
APPY: 1.71 (-0.01)
Venaxis to Present at ICV Company Outreach Summit
PR Newswire - Tue Jul 01, 3:10PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will participate in the third annual ICV Company Outreach Summit, being held July 9-10, 2014, in Montauk, New York. Steve Lundy, President and CEO of Venaxis® will be presenting at the conference to investors including representatives from hedge and private equity funds as well as high net worth individuals and family funds.
APPY: 1.71 (-0.01)
Venaxis Files for FDA Clearance of APPY1 Test
PR Newswire - Mon Mar 31, 6:30AM CDT
CASTLE ROCK, Colo., March 31, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis(TM) has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration (FDA).
APPY: 1.71 (-0.01)
REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
CBI: 39.14 (-1.17), ARLP: 41.81 (-1.65), ALOG: 85.14 (-1.54), BJRI: 48.23 (-0.06), CENTA: 8.40 (+0.16), APPY: 1.71 (-0.01)
NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
APPY: 1.71 (-0.01), ALL: 67.42 (-1.64)
Analysis of the LED Lighting Market in the GCC
PR Newswire - Tue Feb 04, 7:42AM CST
Reportbuyer.com just published a new market research report:
APPY: 1.71 (-0.01)
Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1(TM) Test
PR Newswire - Fri Jan 24, 6:33AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
MDT: 72.52 (-1.25), SIMG: 6.76 (-0.10), MWW: 4.22 (-0.08), APPY: 1.71 (-0.01), NYT: 12.97 (-0.08), AAPL: 109.73 (-1.89), RFMD: 15.50 (-0.29), LF: 4.60 (-0.03)
Spinnaker Support Achieves Record Results and Market Traction in 2013
PR Newswire - Thu Jan 23, 6:00AM CST
Spinnaker Support, a global market leader for SAP, JD Edwards, and Siebel third-party maintenance, application/technical management services, and consulting, today announced a year of tremendous growth as a result of its record-breaking sales and market share gains.
APPY: 1.71 (-0.01)
Social Media Marketing University Announces Its December 2013 Master Certification Program Graduates
PR Newswire - Wed Jan 15, 7:30AM CST
Social Media Marketing University (SMMU) announced today that 8 students received their Master Certification in December. Each student was required to take six core courses and two electives, and pass the program exam. Students have up to one year to complete the program.
APPY: 1.71 (-0.01)
Venaxis Files Response to FDA's Request for Additional Information
PR Newswire - Wed Dec 03, 3:35PM CST
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood-based test designed to aid emergency room clinicians in identifying children, adolescent, and young adult patients who are at low risk for appendicitis, today announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission. Venaxis will provide a business update, including discussion on the APPY1 FDA submission, on Monday, December 8, 2014, at 4:30 p.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 1.71 (-0.01)
Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:32AM CST
Venaxis, Inc. (APPY) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
ICUI: 80.95 (-1.04), GWPH: 72.41 (+1.18), APPY: 1.71 (-0.01), OSUR: 9.49 (-0.25)
Venaxis to Present at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum
PR Newswire - Thu Nov 13, 3:15PM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will be presenting at the Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum being held in New York on November 20, 2014.
APPY: 1.71 (-0.01)
Venaxis: Latest Clinical Data Reveals Huge Market Potential
Blair O'Neill - Seeking Alpha - Wed Oct 29, 10:48AM CDT
Introduction The APPY1 test is a 20 minute diagnostic tool that can be used to rule out the presence of acute appendicitis for the expected price of $80. Venaxis' ( APPY ) goal for the APPY1 test is to reduce the number of CT scans, the use of...
APPY: 1.71 (-0.01)
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ACEP14
PR Newswire - Mon Oct 27, 3:30PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low probability for appendicitis, today announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14). The clinical trial involved 29 U.S. hospital sites recruiting patients aged 2 - 20 from January 2013 through January 2014. Results were presented by Lead Principal Investigator Dr. David S. Huckins, M.D.
APPY: 1.71 (-0.01)
Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14
PR Newswire - Tue Oct 14, 3:05PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low probability for appendicitis, today announced that results of the company's pivotal APPY1 clinical trial will be presented by Dr. David S. Huckins, M.D., Lead Principal Investigator, at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
APPY: 1.71 (-0.01)
Venaxis to Present at September Investor Conferences
PR Newswire - Thu Aug 28, 8:15AM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will present at three upcoming investor conferences: the Rodman & Renshaw 16th Annual Global Investment Conference being held in New York on September 8-10, 2014, the Aegis Capital 2014 Healthcare & Technology Conference being held in Las Vegas on September 10-13, 2014, and the 5th Annual Craig-Hallum Alpha Select Conference being held in New York on September 18, 2014.
APPY: 1.71 (-0.01)
Venaxis to Provide Business Update, including FDA Submission Update
PR Newswire - Thu Aug 07, 3:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will provide a business update, including discussion on the progress of the APPY1 FDA submission, on Monday, August 11, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 1.71 (-0.01)
Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference
PR Newswire - Tue Aug 05, 3:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity 34th Annual Growth Conference, to be held August 13-14, 2014, at the Intercontinental Boston in Boston, MA.
APPY: 1.71 (-0.01)
AspenBio Pharma Down 15.9%, Shares Slide into the Red (APPY)
Comtex SmarTrend(R) - Wed Jul 16, 10:07AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 15.9% to $1.88 on 6.3x average daily volume. AspenBio Pharma has traded 1.3 million shares thus far today, vs. average volume of 206,000 shares per day. The stock has underperformed the Dow (-15.9% to the Dow's 0.2%) and underperformed the S&P 500 (-15.9% to the S&P's 0.2%) during today's trading.
APPY: 1.71 (-0.01)
Venaxis Reports on Recent FDA Submission Activities
PR Newswire - Wed Jul 16, 8:15AM CDT
CASTLE ROCK, Colo., July 16, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, updated on recent activities concerning its U. S. Food and Drug Administration (FDA) submission for the APPY1 Test that was filed in March 2014. The FDA has reviewed the submission, and provided Venaxis with questions and information requests on the submission.
APPY: 1.71 (-0.01)
Venaxis to Present at ICV Company Outreach Summit
PR Newswire - Tue Jul 01, 3:10PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will participate in the third annual ICV Company Outreach Summit, being held July 9-10, 2014, in Montauk, New York. Steve Lundy, President and CEO of Venaxis® will be presenting at the conference to investors including representatives from hedge and private equity funds as well as high net worth individuals and family funds.
APPY: 1.71 (-0.01)
Venaxis Files for FDA Clearance of APPY1 Test
PR Newswire - Mon Mar 31, 6:30AM CDT
CASTLE ROCK, Colo., March 31, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis(TM) has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration (FDA).
APPY: 1.71 (-0.01)
REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
CBI: 39.14 (-1.17), ARLP: 41.81 (-1.65), ALOG: 85.14 (-1.54), BJRI: 48.23 (-0.06), CENTA: 8.40 (+0.16), APPY: 1.71 (-0.01)
NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
APPY: 1.71 (-0.01), ALL: 67.42 (-1.64)
Analysis of the LED Lighting Market in the GCC
PR Newswire - Tue Feb 04, 7:42AM CST
Reportbuyer.com just published a new market research report:
APPY: 1.71 (-0.01)
Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1(TM) Test
PR Newswire - Fri Jan 24, 6:33AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
MDT: 72.52 (-1.25), SIMG: 6.76 (-0.10), MWW: 4.22 (-0.08), APPY: 1.71 (-0.01), NYT: 12.97 (-0.08), AAPL: 109.73 (-1.89), RFMD: 15.50 (-0.29), LF: 4.60 (-0.03)
Spinnaker Support Achieves Record Results and Market Traction in 2013
PR Newswire - Thu Jan 23, 6:00AM CST
Spinnaker Support, a global market leader for SAP, JD Edwards, and Siebel third-party maintenance, application/technical management services, and consulting, today announced a year of tremendous growth as a result of its record-breaking sales and market share gains.
APPY: 1.71 (-0.01)
Social Media Marketing University Announces Its December 2013 Master Certification Program Graduates
PR Newswire - Wed Jan 15, 7:30AM CST
Social Media Marketing University (SMMU) announced today that 8 students received their Master Certification in December. Each student was required to take six core courses and two electives, and pass the program exam. Students have up to one year to complete the program.
APPY: 1.71 (-0.01)
